Zobrazeno 1 - 10
of 31
pro vyhledávání: '"Pavel Trunečka"'
Autor:
Styrbjörn Friman, MD, PhD, Giuseppe Tisone, MD, Frederik Nevens, MD, PhD, Frank Lehner, MD, Walter Santaniello, MD, Wolf O. Bechstein, MD, PhD, Sergey V. Zhuvarel, MD, Helena Isoniemi, MD, PhD, Oleg O. Rummo, MD, Jürgen Klempnauer, MD, Swapneel Anaokar, MBBS, MD, Martin Hurst, MBBS, FRCP, Gbenga Kazeem, PhD, Nasrullah Undre, PhD, Pavel Trunečka, MD, PhD
Publikováno v:
Transplantation Direct, Vol 7, Iss 8, p e722 (2021)
Background. Immunosuppression with calcineurin inhibitors (CNIs) is reportedly associated with risk of renal impairment in liver transplant recipients. It is believed that this can be mitigated by decreasing initial exposure to CNIs or delaying CNI i
Externí odkaz:
https://doaj.org/article/03070658369a4d6a8b22fd3cb723f616
Autor:
Irena Míková, Denisa Kyselová, Kateřina Dvořáková, Monika Dezortová, Milan Hájek, Monika Cahová, Helena Daňková, Věra Lánská, Julius Špičák, Pavel Trunečka
Publikováno v:
Gastroenterologie a hepatologie. 76:429-441
Summary: Introduction: Insulin resistance (IR) is a hallmark of non-alcoholic fatty liver disease (NAFLD), which has been associated with worse long-term survival and more frequent occurrence of chronic kidney disease (CKD) than in patients without N
Publikováno v:
Gastroenterologie a hepatologie. 76:288-295
Skeletal muscles are the biggest tissue in healthy people (30–40% of total body mass) and they comprise three quarters of total body proteins. Muscle alterations, especially muscle wasting and loss of muscle function, have an indisputable prognosti
Autor:
Ondrej Šeda, Monika Cahová, Irena Míková, Lucie Šedová, Helena Daňková, Marie Heczková, Miriam Brátová, Nikola Ďásková, Denisa Erhartová, Václav Čapek, Blanka Chylíková, Pavel Trunečka
Publikováno v:
Frontiers in Endocrinology, Vol 10 (2019)
Background: Liver transplantation leads to non-alcoholic fatty liver disease or non-alcoholic steatohepatitis in up to 40% of graft recipients. The aim of our study was to assess transcriptomic profiles of liver grafts and to contrast the hepatic gen
Externí odkaz:
https://doaj.org/article/22442d9ca15043bb9332c2579b15864a
Autor:
Pavel Trunečka
Publikováno v:
Vnitřní lékařství. 65:588-594
Spravna indikace je jednim z klicových předpokladů uspěchu transplantacni lecby a je tež významným regulatorem řeseni nepoměru mezi potřebou transplantace a realnou kapacitou transplantacniho programu. Pro zařazeni na cekaci listinu je roz
Publikováno v:
Gastroenterologie a Hepatologie.
Autor:
Ulf Neumann, Didier Samuel, Pavel Trunečka, Jean Gugenheim, Giorgio Enrico Gerunda, Styrbjörn Friman
Publikováno v:
Journal of Transplantation, Vol 2012 (2012)
Allograft reinfection with hepatitis C virus (HCV) occurs universally in liver transplant recipients. Corticosteroids can contribute to HCV recurrence. This randomized study evaluated HCV recurrence in HCV-positive liver allograft recipients using st
Externí odkaz:
https://doaj.org/article/5271c6528e01479a8938ddcb4b57f79c
Autor:
Pavel Trunečka
Publikováno v:
Current Opinion in Organ Transplantation. 22:118-122
PURPOSE OF REVIEW To provide latest information on differences between standard tacrolimus (TAC BID) and slow-released formulation of tacrolimus (Advagraf) in liver transplantation (LTx), and to discuss the latter's therapeutic value as a distinct en
Autor:
Martin, Oliverius, Libor, Janoušek, Michal, Kudla, Petr, Wohl, Jan, Kopecký, Eva, Kieslichová, Dana, Němcová, Pavel, Trunečka, Pavel, Drastich, Eva, Honsová, Dana, Kautznerová, Hana, Baštová, Bohumila, Heřmanová, Jiří, Froněk
Publikováno v:
Casopis lekaru ceskych. 156(7)
Intestinal transplantation represents a suitable treatment for patients with intestinal failure who then develop life-threatening complications of total parenteral nutrition and for some patients with complex abdominal disorders not suitable for conv
Publikováno v:
Clinical Transplantation. 25:E1-E12
This study assessed the long-term effects of prolonged-release tacrolimus (Advagraf(®) [Tacrolimus QD]), which has been developed to provide similar efficacy and safety to twice-daily tacrolimus (Prograf(®) [Tacrolimus BID]) with the added benefit